Stocks / Stock overview

Medline Inc. (MDLN)

$34.26+5.16%Aft $34.32 (+0.17%)Market cap $46.09B

NasdaqGS · Price as of · Nasdaq Real Time Price

Stock Scorer
Scoring…
Analyst consensus
Buy$44.62
  • Analysts26
  • Implied upside+30.2%
  • Target range$34.00 to $55.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
November 4, 2026date estimated
  • EPS expected$0.35
  • Revenue expected$7.72B
  • Estimate range$0.28 to $0.47
Consensus of 22 analysts for the quarter ending September 30, 2026. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
4August 21, 20264
4August 21, 20264
4August 17, 20264
SCHEDULE 13G/AAugust 11, 2026View on EDGAR
4August 11, 20264
4August 7, 2026OWNERSHIP DOCUMENT
SCHEDULE 13G/AAugust 7, 2026View on EDGAR
4August 7, 20264
All SEC filings

Frequently asked questions

When does MDLN report earnings?

Medline Inc. (MDLN) is scheduled to report quarterly results on November 4, 2026 (estimated). The 22-analyst consensus is $0.35 per share on revenue of $7.72B for the quarter ending September 30, 2026. The date is an estimate from past reporting patterns and can move until the company confirms it.

What do analysts expect for MDLN?

26 analysts cover Medline Inc. (MDLN). The consensus rating is Buy. The average price target is $44.62, in a range of $34.00 to $55.00.

Are insiders buying or selling MDLN?

We have no qualifying Form 4 insider purchases or sales on record for Medline Inc. (MDLN). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see MDLN SEC filings?

Recent filings are listed on this page, newest first. The latest is a 4 filed August 21, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.